請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35820
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
dc.contributor.author | I-Chen Lai | en |
dc.contributor.author | 賴伊貞 | zh_TW |
dc.date.accessioned | 2021-06-13T07:11:54Z | - |
dc.date.available | 2008-08-03 | |
dc.date.copyright | 2005-08-03 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-26 | |
dc.identifier.citation | 1.El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35:S72-8.
2.Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-42. 3.Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001;13:777-84. 4.Hino O, Kajino K, Umeda T, Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 2002;37:883-7. 5.Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-308. 6.Kao JH, Chen DS. Recent research progress in hepatocellular carcinoma. J Formos Med Assoc 2002;101:239-48. 7.Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41. 8.Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400. 9.Bosch FX, Ribes J. The epidemiology of primary liver cancer: global epidemiology. Viruses and Liver Cancer 2002;1-16. 10.Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50. 11.Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76. 12.Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002;123:1323-30. 13.Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002;296:1635-6. 14.Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004;11:271-6. 15.Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503. 16.Huang SN, Chen TC, Tsai SL, Liaw YF. Histopathology and pathobiology of hepatotropic virus-induced liver injury. J Gastroenterol Hepatol 1997;12:S195-217. 17.Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002 ;23(4):201-8. 18.Miyazoe S, Hamasaki K, Nakata K, Kajiya Y, Kitajima K, Nakao K, Daikoku M, Yatsuhashi H, Koga M, Yano M, Eguchi K. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002;97:2086-92. 19.Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH, Kim YJ, Lee HS. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 2003;12:901-6. 20.Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, Tur-Kaspa R, Klein T. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-50. 21.Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46:540-5. 22.Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003;104:617-23. 23.Akahoshi M, Nakashima H, Miyake K, Inoue Y, Shimizu S, Tanaka Y, Okada K, Otsuka T, Harada M. Influence of interleukin-12 receptor beta-1 polymorphisms on tuberculosis. Hum Genet 2003;112:237–243. 24.Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-6. 25.Schroppel B, Fischereder M, Ashkar R, Lin M, Kramer BK, Mardera B, Schiano T, Murphy B. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002;2:640-5. 26.Hoebee B, Rietveld E, Bont L, Oosten M, Hodemaekers HM, Nagelkerke NJ, Neijens HJ, Kimpen JL, Kimman TG. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J Infect Dis 2003;187:2-11. 27.Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000;43:124-7. 28.Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51. 29.Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51. 30.Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-64. 31.Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M, Grappone C, Pellegrini G, Benedetti A, Surrenti C, Casini A. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 2005;41:1074-84. 32.NE Breslow & NE Day. Design consideration in: Statistical Methods in Cancer Research. Lyoncedex, France: International Agency for Research on Cancer, 1987: 297. 33.Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997;99:3025-33. 34.Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-30. 35.Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-12. 36.King JK, Yeh SH, Lin MW, Liu CJ, Lai MY, Kao JH, Chen DS, Chen PJ. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology 2002;36:1416-24. 37.Fernandez-Arcas N, Blanco A, Gaitan MJ, Nyqvist M, Alonso A, Reyes-Engel A. Differential transcriptional expresion of the polymorphic myxovirus resistance protein A in response to interferon-alpha treatment. Pharmacogenetics 2004;14:189-93. 38.Lewandowska M, Franciszkiewicz K, Prokop J, Ofori H, Jagodzinski PP. Distribution of two HIV-1-resistant polymorphisms (SDF1-3'A and CCR2-64I alleles) in the Polish population. J Hum Genet 2002;47:585-9. 39.Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K, Imawari M. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997;158:5283-91. 40.Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82. 41.Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30. 42.Zhang X, Miao X, Sun T, Tan W, Ou S, Xiang P, Zhou Y, Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-84. 43.Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001;32:250-6. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35820 | - |
dc.description.abstract | 背景/目的:慢性B與C型肝炎病毒(HBV, HCV)感染是肝細胞癌(hepatocellular carcinoma, HCC)的重要危險因子。HBV, HCV持續感染導致肝細胞發炎、壞死是誘導HCC發展的主要致癌機轉,細胞激素在免疫與發炎反應過程中扮演重要角色。本研究目的在利用病例對照研究分析細胞激素基因多形性和HCC的關係,由於男女性的病因有可能不同,我們特別對男女性的HCC進行個別分析。
材料與方法:研究個案包括989名男性新發病病例和956名男性對照,所有的男性個案均為HBsAg帶原者;女性有362名新發病病例和426名對照進入研究。我們分析14種細胞激素的單一核苷酸基因多形性(single nucleotide polymorphism, SNP)與HCC的關係,這些SNP所在基因牽涉pro-inflammation(IL12Rβ1+641、IL12Rβ1+1094 )、anti-inflammation(IL4-590、IL4R+50、IL6-174、IL10-592、IL10-819、IL10-627) 、fibrosis與apoptosis(Fas-1377、Fas-670、FasL-844)、影響α-interferon治療效果(MxA-88),或chemokines(SDF1-3’、CCR2-190)的功能。利用非條件式羅吉斯迴歸模式進行危險比(odds ratio, OR)與95%信賴區間(95% confidence interval, 95%CI)的估計。 結果:對於男性,多重檢定校正後,沒有一個SNP或haplotype和HCC顯著相關。對於女性,在多重檢定校正後,只有Fas-670和HCC呈顯著相關(P=0.0012),Fas-1377和Fas-670具強連鎖不平衡現象(D’=0.91),分析這兩個基因所組成之haplotype,發現帶有兩條 Fas haplotype 3 [-1377G; -670A]者相對於不帶Fas haplotype 3者,其HCC的OR值在調整後為1.8(95% CI = 1.2-2.8)。我們也發現Fas-1377和Fas-670所組成的haplotype和FasL-844具顯著的交互作用(P=0.0176),對帶有兩條Fas haplotype 3者,其FasL-844為TT, TC和CC調整後的OR值各為1.0, 4.33(95% CI= 1.24-15.09), 3.02(95% CI= 0.88-10.42);在帶一條或不帶Fas haplotype 3者,FasL-844的TC和CC基因型則不增加HCC危險性。 結論:Fas-1377和-670所組成haplotype與FasL-844對於女性HCC發生的危險性具交互作用。 | zh_TW |
dc.description.abstract | Background Chronic infection with hepatitis B or C virus is an important risk factor for hepatocellular carcinoma (HCC). Persistent viral infection leads to hepatic inflammation and then necrosis, which is the main mechanism causing HCC. Cytokine plays an important role in immunity and the production of inflammatory response. We conducted a case-control study to analyze the association between cytokine polymorphisms and HCC risk.
Materials and Methods Genotyping was performed for a total of 1351 (989 males and 362 females) case patients and 1382 (956 males and 426 females) control subjects. We analyzed 14 single nucleotide polymorphisms (SNPs) in the genes involving proinflammation (IL12Rβ1+641, IL12Rβ1+1094 ), anti-inflammation (IL4-590, IL4R+50, IL6-174, IL10-592, IL10-819, IL10-627), apoptosis (Fas-1377, Fas-670, FasL-844), anti-viral effect (MxA-88), or chemokines (SDF1-3’, CCR2-190). Unconditional logistic regression was used to calculate odds ratio (OR) and 95% confidence intervals (CIs). Results For males, none of the 14 SNPs were significantly associated with HCC after adjusting multiple comparisons. For females, Fas-670 was significantly associated with HCC (P=0.0012). Fas-1377 was in linkage disequilibrium (D’=0.91) with Fas-670. Haplotype analysis also revealed that homozygosity for the Fas-1377G-670A haplotype was significantly associated with HCC, showing an adjusted OR of 1.8 (95% CI=1.2-2.8), when compared with individuals carrying zero copy of this haplotype. The Fas-1377G-670A haplotype modified the association between FasL-844 and HCC (P for interaction=0.0176). Among homozygotes of the Fas-1377G-670A haplotype, the ORs of HCC associated with the TT, TC, and CC genotype of the FasL-844 were 1.00, 4.33 (95% CI=1.24-15.09), and 3.02 (95% CI=0.88-10.42), respectively. By contrast, no association between FasL-844 and HCC was observed among individuals carrying zero or one copy of the Fas-1377G-670A haplotype. Conclusion Fas-1377G-670A haplotype modified the effect of the FasL-844 on the development of HCC in females. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T07:11:54Z (GMT). No. of bitstreams: 1 ntu-94-R91842005-1.pdf: 5765587 bytes, checksum: 31c182a705d06e8ad9d60ea326389bb5 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 目錄
前言 1 材料與方法 5 研究個案 5 問卷資料 6 實驗分析 6 統計方法 7 結果 8 討論 10 參考文獻 14 表目錄 表一 病例與對照個案的基本特徵分佈 19 表二 男性個案基因型分佈 20 表三 女性個案基因型分佈 22 表四 和男性肝細胞癌顯著相關SNP 25 表五 和女性肝細胞癌顯著相關SNP 26 表六 女性個案Haplotype分析 27 表七 女性肝細胞癌之Fas-1377和-670所組成haplotype與FasL-844基因多形性之交互作用 28 附錄目錄 一、研究個案全血DNA的萃取 i 二、聚合酶連鎖反應 i 三、限制片段長度多形性 ii 附表一 PCR所使用的引子序列及產物大小 iv 附表二 各基因多形性所需的限制酶和切割基因型的大小 v 附表三 Real-time PCR各基因多形性所使用的引子及探針序列 vi 附錄圖 vii | |
dc.language.iso | zh-TW | |
dc.title | 細胞激素基因多形性與肝細胞癌的危險性 | zh_TW |
dc.title | Cytokine Genetic Polymorphisms and Risk of Hepatocellular Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李文宗(Wen-Chung Lee),陳建仁(Chien-Jem Chen),蕭朱杏(Chu-hsin Hsiao),何美鄉(Mei-Shang Ho) | |
dc.subject.keyword | 細胞激素,單一核苷,酸基因多形性,B型肝炎,C型肝炎,肝細胞癌,病例對照研究,基因交互作用, | zh_TW |
dc.subject.keyword | cytokine,single nucleotide polymorphism,hepatitis B,hepatitis C,hepatocellular carcinoma,case-control study,gene-gene interaction, | en |
dc.relation.page | 55 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-07-27 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 5.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。